News & Media

Latest Press

Featured In

In the Press

yahoo_finance

September 15, 2021

Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders

Click to Read More


yahoo_finance

September 13, 2021

Todos Medical to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

Click to Read More


yahoo_finance

September 13, 2021

These OTCQX & OTCQB Securities Had the Most Trading Activity in August

Click to Read More


Seeking-alpha_logo

September 7, 2021

Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19

The other 3CL protease inhibitor competitor is a longshot nano-cap company called Todos Medical. Todos is similar to AB Science as it has a promising pipeline of products including its 3CL protease. Other cutting-edge developments include; automated labs for new diagnostic tools for breast cancer and Alzheimer's, as well as a diagnostic platform technology. Its 3CL protease inhibitor is called Tollovir. It is an antiviral, but it is also designed to support immune function. They also have a dietary supplement made of the same active ingredient that supports immune function.

Click to Read More


Proactive-Logo

September 3, 2021

Todos Medical completes validation of COVID-19 and respiratory panel tests

Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel (NASDAQ:QDEL) (NASDAQ:QDEL) Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production.

Commissiong says kits will be produced alongside COVID PCR tests currently being run (Provista Respiratory Panel) and expects this new respiratory panel to be launched in September 2021.

Click to Read More


yahoo_finance

September 2, 2021

Todos Medical launches test that measures COVID-19 antibody levels

Gerald Commissiong, CEO of Todos Medical, joins Yahoo Finance to discuss the latest in antibody test innovation.

Click to Read More


Proactive-Logo

September 1, 2021

Todos Medical says its Provista lab completes validation of combo COVID-19, Influenza A & B, and RSV & hMPV respiratory panel test

Todos Medical Ltd. has announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel (NASDAQ:QDEL) Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production.

The company said kits will be produced alongside COVID PCR tests currently being run (Provista Respiratory Panel) and expects this new respiratory panel to be launched in September 2021.

The validation coincides with the recent validations for the cPass semi-quantitative COVID neutralizing antibody test and the Kogene COVID variant detection kits also being launched in September 2021.

Click to Read More


financial-buzz_logo

August 27, 2021

Breaking News: Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Kogene Biotech PCR Variant Test Kit (‘Kogene Variant Kit’) into production and expects to launch variant testing in September 2021. The Kogene Variant Kit is a PCR kit capable of identifying the key mutations associated with specific SARS-CoV-2 variants, including the key P681R mutation identified in the Delta variant, that allows Todos to categorize the lineage of the strain responsible for a positive test result. The test can be completed in as little as one hour, significantly faster than genome sequencing, and is highly scalable with the Tecan® liquid handling automation currently onsite at Provista.

Click to Read More


bio_pharm

August 25, 2021

Todos Medical to Launch New Antibody Blood Test for COVID-19

Todos Medical has completed validation of its cPass neutralizing antibody blood test to monitor COVID-19 immunity.

Todos Medical, a medical diagnostics company, announced that its lab, Provista Diagnostics, has successfully completed the validation studies required to put its cPass neutralizing antibody blood test into production. The company expects to launch the new test in September 2021, and Provista Diagnostics can do up to 20,000 polymerase chain reaction tests and over 1500 cPass tests per day, according to a company press release.

The blood test received Emergency Use Authorization from FDA for the detection of neutralizing antibodies (NAbs) that could be used to monitor key biomarkers of COVID-19. Individuals who acquired their immunity through either vaccination or natural infection will be able to monitor their immunity levels with the device.

Click to Read More


Screen Shot 2021-09-10 at 3.04.24 PM

August 24, 2021

Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers

Agreement will enable Meadowlands Diagnostics to offer cPass testing for COVID-19 immunity monitoring to its growing customer base including two additional New Jersey School system contracts

New York, NY, and Tel Aviv, ISRAEL, Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has entered into a reference lab agreement to provide cPass neutralizing antibody blood testing services to Meadowlands Diagnostics, a CLIA-certified New Jersey-based provider of laboratory testing services.

Click to Read More


topnewsguide

August 24, 2021

Todos Medical Ltd (TOMDF) Stock More Than Doubled: But Why?

Medical diagnostics and associated solutions firm Todos Medical Ltd (OTCMKTS:TOMDF) started the week off with a bang as its stock went up by more than 100% on Monday and in light of such gains, it might be worthwhile to take a look at the announcement that set the rally off.

Yesterday, it was announced by the company that its Chief Executive Officer Gerald Commissiong was going to make an appearance on the show named Varney & Co on the Fox Business Networks yesterday. Considering the fact that Varney & Co is a popular show, the reaction to the news in the markets was understandable and on top of that, the main subject of the discussion may have been a factor as well.

Click to Read More


Screen Shot 2021-09-10 at 2.59.06 PM

August 24, 2021

Top Covid Stocks In Play After Pfizer Vaccine Approval: TOMDF ENZC TSOI

With the FDA approval of the Pfizer-BioNTech vaccination many biotech stocks moved higher. Leading the microcaps was Todos Medical (OTCMKTS: TOMDF). Shares of leading vaccines makers Pfizer (NYSE: PFE), BioNTech (NASDAQ: BNTX), and Moderna (NASDAQ: MRNA) moved higher on the news due to anticipation of future approvals. The White House immediately took advantage of this approval to pitch the vaccine after hours in a press conference with President Biden claiming that COVID-19 was now a pandemic of the unvaccinated.

Click to Read More


yahoo_finance

August 23, 2021

Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity

New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:40 AM Eastern Time today. Mr. Commissiong will discuss the planned launch of cPass neutralizing antibody testing at the Company’s Provista Diagnostics laboratory and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States.

Click to Read More


yahoo_finance

August 23, 2021

Proactive news headlines including Endeavour Mining, PayPal, Alternus Energy, Phunware, Todos Medical and Orgenesis

Click to Read More


yahoo_finance

August 17, 2021

Todos to Present at Upcoming Emerging Growth Conference

Click to Read More


Screen Shot 2021-09-10 at 3.33.49 PM

August 9, 2021

The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle

Todos Medical Ltd. (OTCQB: TOMDF) announced last week that, "it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark for the Company's proprietary supplement Tollovid™. The Company received a Certificate of Free Sale (CFS) for the 5-day high dose regimen of Tollovid from the US Food & Drug Administration (US FDA) in April 2021.

Click to Read More


financial-buzz_logo

August 6, 2021

“Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Notice of Allowance for Tollovid

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™.”

Click to Read More


yahoo_finance

August 5, 2021

Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™

This USPTO notice of allowance underscores the desire in the marketplace for Tollovid, especially given its high dose, 5-day formulation that helps to support and maintain healthy immune function. Tollovid is a potent botanical, delayed release, bioavailable 3CL protease inhibitor. The Company’s lower dose, delayed release, daily-use formulation Tollovid Daily™ received a CFS from the US FDA in July 2021, including the critical 3CL protease inhibitor claim. Tollovid has high 3CL protease inhibitor activity than Tollovid Daily.

Click to Read More


Screen Shot 2021-09-13 at 11.55.01 AM

August 1, 2021

50 Smartest Companies of the Year 2021:

Todos Medical is Helping Create a Healthier Future With its Ace Cancer Screening Technology

Click to Read More


yahoo_finance

July 28, 2021

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

Click to Read More


Screen Shot 2021-09-13 at 11.01.24 AM

July 19, 2021

Todos Medical, Fosun Pharma Ink Distribution Agreement for SARS-CoV-2 Neutralizing Antibody Test

Click to Read More


Proactive-Logo

July 15, 2021

Todos Medical updates on Phase 2 trial progress to treat hospitalized coronavirus patients in Israel

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong updated Proactive on progress of enrollment of its Phase 2 clinical trial to treat hospitalized coronavirus patients in Israel, with its TolloTest biomarker being used for the first time as a surrogate biomarker to monitor patient response to treatment. Commissiong says recruitment is 'picking up again' due to an increase in coronavirus caseload in Israel.

Click to Read More


financial-buzz_logo

July 1, 2021

Breaking News: Todos Medical Provides End of Second Quarter 2021 Corporate Update

“The first half of 2021 has seen a dramatic shift in the COVID-19 marketplace in the United States,” said Gerald E. Commissiong, President & CEO of Todos Medical. “In light of the emerging Delta variant circulating widely in the US, there is now a clear need for novel COVID-19 antiviral therapies to protect the unvaccinated and those for whom authorized vaccines do not confer immunity, which includes a large portion of the elderly and those taking immune suppressants, against COVID-19 infection..."

Click to Read More


Screen Shot 2021-09-13 at 10.40.20 AM

June 19, 2021

Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral

TOMDF could beat PFE to the punchline, and if they do, its a multibillion dollar lottery ticket for TOMDF shareholders with only 3 names in the drawing if you you think Merck (MRK) has a chance with molnupiravir.

Investors are bound to reap the rewards from the company that quickly finds the best solution. PFE or TOMDF’s 3CL protease inhibitor is a viable solution to be COVID-19’s Tamiflu, or the Tamiflu for coronaviruses in general. The real question is whether or not they can get it approved in time before the variants decrease the effectiveness of the vaccines.

Click to Read More


Seeking-alpha_logo

June 17, 2021

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Click to Read More



fox2_logo

June 10, 2021

"The question we've got to ask ourselves is: is this something we can stop or is it inevitable?" said Todos Medical CEO Gerald Commissiong..."
Click to Read More


healthline_logo

June 3, 2021

Entrepreneurs Are Betting Big on NYC Covid-19 Testing Businesses

Some are getting creative launching or expanding companies, which they believe will be profitable for a long time“It’s likely that it will become endemic because people carry it without knowing or showing symptoms, and some people have diminished immunity that will continue to make them susceptible even post-vaccination,” said Gerald Commissiong..." 
Click to Read More


univision_logo

June 2, 2021

"We do not see significant cause for concern because avian flu viruses are significantly less virulent than coronaviruses and have a more difficult time spreading from person to person."
Click to Read More


dailymail_logo

May 17, 2021

Hopes of Covid breakthrough as Australian scientists develop antiviral injection to kill 99.9% of the virus in the lungs of mice – but it won't be ready for humans until 2023

"Tollovir is being trialled on people by the company Todos Medical in Israel. Todos Medical said past research had shown the drug could work against coronaviruses in general and that it had potential to 'significantly reduce' the severity of Covid."
Click to Read More


dailymail_logo

April 26, 2021

Pfizer's anti-Covid pill may be ready this YEAR as first human trials are set to end in May – as expert studying another antiviral says effective drugs could end lockdowns forever

Covid-specific therapies being developed include molnupiravir, by Merck and Ridgeback Biotherapeutics; Tollovir, by Todos Medical; and NT-300 by Romark.

Click to Read More


dailymail_logo

April 20, 2021

A PILL to kill third wave: Boris Johnson launches 'ambitious' new 'antivirals taskforce' so Britons can take tablets for Covid at home 'by autumn'

Another, called Tollovir, is being trialled on people by the company Todos Medical in Israel. Todos Medical said past research had shown the drug could work against coronaviruses in general and that it had potential to 'significantly reduce' the severity of Covid. 

Click to Read More


wsj_logo

March 16, 2021

Entrepreneurs Are Betting Big on NYC Covid-19 Testing Businesses

Some are getting creative launching or expanding companies, which they believe will be profitable for a long time

"Manhattan-based Todos Medical mainly develops cancer-detection tests. But next month it will launch what it believes to be the city’s first mobile Covid-testing labs."
Click to Read More


Stay informed of our latest breakthroughs.